Abgent

Abgent develops novel proteomic reagents for cell signaling, apoptosis, cell cycle regulation, and genetic diseases. Our custom services include monoclonal and polyclonal antibody development/purification, protein expression in bacteria/baculovirus, and peptide synthesis. Our powerful tools profile protein function, interaction, cellular location, expression, and post-translational modification.

Activity:

- Contract Research
- Licensing & Business Development
- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Proteins
- Reagents
- Technology

Therapeutic targets:

- Cancer
- Infectious Diseases

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe , Asia , Far East , Australia/New-Zealand , Near/Middle East , Central/South America , Africa

c. Countries active: United States of America

Corporate data:

Number of Employees: 25

Turnover:

Amount:	Year:	Currency:
1 million	2002	US Dollar

Year founded: 2002